Goldman Sachs analysts added Johnson & Johnson to the firm’s US Conviction List as part of its monthly update. Goldman says Johnson & Johnson offers a “stable, defensive grower with the industry’s strongest balance sheet,” which allows for continued investments in the innovative medicines segment to augment revenue growth. The firm has a Buy rating on the shares with a $172 price target
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on JNJ:
- Johnson & Johnson Shareholders Approve 2025 Director Nominees
- Johnson & Johnson receives FDA approval for Imaavy in myasthenia gravis
- Johnson & Johnson price target raised to $184 from $180 at HSBC
- Johnson & Johnson’s Strategic Advancements in Electrophysiology: A Buy Rating by Josh Jennings
- Johnson & Johnson announces new data from Cohort 2 of Phase 2b SunRISe-1